Next-Generation-Sequencing Approach to Neutropenic Sepsis

Launched by BORIS BÖLL · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method called Next-Generation Sequencing (NGS) to help find infections in patients who have a low white blood cell count, a condition known as neutropenia. Neutropenic patients often have a fever or signs of sepsis (a serious infection that can affect organ function), and this study aims to see if the NGS approach can quickly and accurately detect bloodstream infections in these patients.

To participate in the trial, you need to be at least 18 years old and able to give your consent. You must also have neutropenia, which is defined as having fewer than 500 neutrophils (a type of white blood cell) in your blood, or fewer than 1000 white blood cells if the specific count isn't available. If you join the study, you can expect to undergo tests that will help researchers understand how well this new method works for diagnosing infections in patients like you. It's important to know that if you're already in the hospital for a different episode of fever, you can't participate again for the same hospitalization, and the study isn't open to those who are close to death.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Informed consent
• • Neutropenia defined as \<500 ANC (Absolute neutrophil Count)/µl or \<1000 WBC (White bloddcell Count)/µl if ANC is not available
• • Fever (with an onset \< 24h) or Sepsis (with an onset \<24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.
• Exclusion Criteria:
• • Age \< 18 years
• • Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
• • Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
• • Death is deemed imminent and inevitable